Table 2.
Participant characteristics
| Total group (N = 50) |
Amyloid-beta positive (n = 23) |
Amyloid-beta negative (n = 27) |
p-value | |
|---|---|---|---|---|
| Age, years, mean ± SD | 68.4 ± 6.2 | 69.6 ± 6.3 | 67.3 ± 6.0 | 0.193a |
| Female, n (%) | 29 (58.0) | 13 (56.5) | 16 (59.3) | 0.845d |
| Education, years, mean ± SD | 15.3 ± 3.8 | 15.2 ± 4.6 | 15.3 ± 3.0 | 0.944b |
| Cohort | 0.233d | |||
| AMYPAD PNHS, n (%) | 34 (68.0) | 13 (56.5) | 21 (77.8) | |
| SCIENCe, n (%) | 12 (24.0) | 8 (34.8) | 4 (14.8) | |
| ADC, n (%) | 4 (8.0) | 2 (8.7) | 2 (7.4) | |
| Amyloid-beta biomarkers | 0.508d | |||
| Cerebrospinal Fluid, n (%) | 5 (10.0) | 3 (13.0) | 2 (7.4) | |
| Positron Emission Tomography, n (%) | 45 (90.0) | 20 (87.0) | 25 (92.6) | |
| Mini-Mental State Examination, mean ± SD | 29.2 ± 1.0 | 28.8 ± 1.1 | 29.5 ± 0.7 | 0.012c |
Note Data are depicted as mean ± standard deviation (SD) unless otherwise indicated; Differences between amyloid-beta positive individuals and amyloid-beta negative individuals are tested . aStudent t-test, bWelch t-test, c Wilcoxon test, dChi-Square test